Who
Robert J. Rubin
Director
Company insider
Files Form 4 as: Director, Soligenix; Director, Biotelemetry; Director, CardioNet; Director, Questcor Pharmaceuticals.
In numbers
- Trades disclosed
- 60
- Buys
- 2
- Sells
- 3
- Bought
- $61K
- Sold
- $1.1M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 24 Sep 2007
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —54 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —74 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —128 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —63 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —121 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —192 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,647 at $0.00 | filing |
| 12 Dec 2024filed 13 Dec 2024 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,646 at $0.00 | filing |
| 15 Dec 2023filed 15 Dec 2023 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,136 at $0.00 | filing |
| 17 Nov 2022filed 21 Nov 2022 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,154 at $0.00 | filing |
| 23 Sep 2021filed 24 Sep 2021 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,126 at $0.00 | filing |
| 9 Feb 2021filed 11 Feb 2021 | Biotelemetry | SEC FORM 4 Code D | $11.6M161,093 at $72.00 | filing |
| 9 Feb 2021filed 11 Feb 2021 | Biotelemetry | SEC FORM 4 Code D | $1.6M22,037 at $72.00 | filing |
| 16 Sep 2020filed 18 Sep 2020 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,228 at $0.00 | filing |
| 11 May 2020filed 13 May 2020 | Biotelemetry | SEC FORM 4 Code A | —4,074 at $0.00 | filing |
| 3 May 2020filed 13 May 2020 | Biotelemetry | SEC FORM 4 Code F | $86519 at $45.51 | filing |
| 6 Sep 2019filed 10 Sep 2019 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,928 at $0.00 | filing |
| 3 May 2019filed 7 May 2019 | Biotelemetry | SEC FORM 4 Code A | —3,450 at $0.00 | filing |
News
Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)SNGX · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Robert J. Rubin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.